Rhythm Pharmaceuticals, Inc. (RYTM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rhythm Pharmaceuticals, Inc. (RYTM) trades at $111.59 with AI Score 23/100 (Grade F). Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing therapeutics for rare genetic diseases of obesity. Market cap: $7.65B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026RYTM stock analysis for 2026: Analysts have set a consensus price target of $135.56 for Rhythm Pharmaceuticals, Inc., suggesting 21.5% upside from the current price of $111.59. The AI MoonshotScore is 23/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
RYTM: 3/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Rhythm Pharmaceuticals, Inc. (RYTM) Healthcare & Pipeline Overview
Rhythm Pharmaceuticals, Inc. specializes in innovative treatments for rare genetic obesity disorders, leveraging its proprietary melanocortin-4 receptor technology to address unmet medical needs in this niche market, distinguished by its lead product IMCIVREE and ongoing clinical trials for additional therapies.
What Is the Investment Thesis for RYTM?
Rhythm Pharmaceuticals, Inc. presents a unique investment thesis characterized by its focus on rare genetic obesity disorders, a market segment with significant unmet needs. The company's lead product, IMCIVREE, has achieved market approval, contributing to a current market capitalization of $7.65B. The ongoing Phase II trials for setmelanotide could further enhance the product pipeline, potentially expanding the addressable market significantly. With a gross margin of 89.4%, the company demonstrates strong operational efficiency, although it currently faces a profit margin of -93.3%. The high beta of 2.14 indicates increased volatility, which investors may want to evaluate. As the company continues to innovate and expand its therapeutic offerings, it stands to benefit from the growing awareness and diagnosis of genetic obesity disorders, which could drive revenue growth in the coming years.
Based on FMP financials and quantitative analysis
RYTM Key Highlights
- Market capitalization of $7.65B reflects strong investor interest in rare genetic therapies.
- Gross margin of 89.4% indicates high product profitability, essential for sustaining operations.
- Current profit margin of -93.3% highlights the challenges of commercialization in the biotech sector.
- Beta of 2.14 suggests significant stock price volatility, typical for biotech firms in clinical stages.
- Lead product IMCIVREE targets a niche market with limited competition, enhancing market positioning.
Who Are RYTM's Competitors?
RYTM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | $189.31 | +0.04% | $40.25B | 56 |
| NUVL Nuvalent, Inc. | $123.73 | -0.00% | $9.10B | 57 |
| ACLX Arcellx, Inc. | $115.07 | +0.02% | $6.73B | 45 |
| PTGX Protagonist Therapeutics, Inc. | $130.90 | -0.55% | $8.42B | — |
| KNSA Kiniksa Pharmaceuticals, Ltd. | $64.50 | -0.04% | $4.85B | 44 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RYTM's Key Strengths?
- Strong proprietary technology platform targeting genetic obesity disorders.
- High gross margin of 89.4% indicating strong product profitability.
- Established market presence with an approved product, IMCIVREE.
What Are RYTM's Weaknesses?
- Current negative profit margin of -93.3% reflecting commercialization challenges.
- Limited product pipeline compared to larger biotech firms.
- High beta of 2.14 indicates stock price volatility.
What Could Drive RYTM Stock Higher?
- Results from ongoing Phase II clinical trials for setmelanotide expected by Q4 2026.
- IMCIVREE's market presence continues to expand as awareness of genetic obesity disorders grows.
- Potential collaborations with additional research institutions to enhance clinical data and product development.
What Are the Key Risks for RYTM?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles may delay the approval of new therapies in the pipeline.
- High volatility in stock price due to market conditions and biotech sector fluctuations.
- Competition from emerging biotech firms targeting similar rare genetic disorders.
What Are the Growth Opportunities for RYTM?
- Growth opportunity 1: The global obesity therapeutics market is expected to reach $60 billion by 2027, driven by increasing obesity rates and a growing understanding of genetic factors. Rhythm's lead product, IMCIVREE, positions the company to capture a significant share of this market as awareness and diagnosis of genetic obesity disorders rise. The company's unique focus on rare conditions provides a competitive advantage in this expanding market.
- Growth opportunity 2: Ongoing clinical trials for setmelanotide in various genetic obesity disorders could lead to additional product approvals, expanding Rhythm's therapeutic portfolio. The potential approval of setmelanotide for conditions like SH2B1 deficiency obesity could significantly increase the addressable market, estimated to be worth $10 billion annually. Successful trial outcomes could drive revenue growth and enhance the company's market position.
- Growth opportunity 3: Collaborations with research institutions and clinical registries, such as the Clinical Registry Investigating Bardet-Biedl Syndrome, can enhance Rhythm's research capabilities and accelerate the development of new therapies. These partnerships not only provide access to valuable data but also strengthen the company's credibility within the scientific community, potentially leading to faster regulatory approvals.
- Growth opportunity 4: The increasing focus on personalized medicine and genetic testing presents an opportunity for Rhythm to leverage its expertise in genetic obesity disorders. As healthcare providers adopt more personalized approaches to treatment, Rhythm can position itself as a leader in developing targeted therapies for rare genetic conditions, capturing a growing segment of the market.
- Growth opportunity 5: Expansion into international markets could provide significant growth potential for Rhythm Pharmaceuticals. As healthcare systems worldwide recognize the importance of addressing rare genetic disorders, Rhythm can explore opportunities in regions with high obesity rates and limited treatment options, thereby increasing its global footprint and revenue potential.
What Opportunities Does RYTM Have?
- Expanding market for obesity therapeutics projected to grow significantly.
- Potential for additional product approvals from ongoing clinical trials.
- Increasing focus on personalized medicine and genetic testing.
What Threats Does RYTM Face?
- Intense competition in the biotechnology sector for rare diseases.
- Regulatory challenges in obtaining approvals for new therapies.
- Market volatility affecting stock performance and investor sentiment.
What Are RYTM's Competitive Advantages?
- Proprietary technology targeting melanocortin-4 receptors provides a competitive edge.
- Focus on rare genetic disorders reduces competition in the market.
- Strong clinical data supporting the efficacy of IMCIVREE enhances market credibility.
What Does RYTM Do?
Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapeutics for rare genetic diseases of obesity. The company was initially known as Rhythm Metabolic, Inc. and rebranded in October 2015 to reflect its broader focus on genetic obesity disorders. Rhythm's flagship product candidate, IMCIVREE, is a potent melanocortin-4 receptor agonist approved for the treatment of obesity due to pro-opiomelanocortin (POMC) deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome, among others. In addition to IMCIVREE, Rhythm is advancing setmelanotide, currently in Phase II clinical trials, targeting various genetic deficiencies leading to obesity, including SH2B1 deficiency and MC4 receptor deficiency. The company has established a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome, enhancing its research capabilities and clinical understanding of these rare conditions. With a workforce of 283 employees, Rhythm Pharmaceuticals is positioned to make significant strides in the biotech sector, focusing on a patient population with limited treatment options and a high unmet medical need.
What Products and Services Does RYTM Offer?
- Develops therapeutics specifically for rare genetic diseases of obesity.
- Commercializes IMCIVREE, a treatment for specific genetic obesity disorders.
- Conducts clinical trials for setmelanotide targeting various genetic deficiencies.
- Collaborates with research institutions to enhance understanding of genetic obesity disorders.
- Focuses on addressing unmet medical needs in the obesity treatment landscape.
How Does RYTM Make Money?
- Generates revenue primarily through the sale of its lead product, IMCIVREE.
- Engages in strategic partnerships and collaborations to enhance research and development.
- Invests in clinical trials to expand its product pipeline and therapeutic offerings.
What Industry Does RYTM Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in genetic research and an increasing focus on personalized medicine. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with a CAGR of around 7.4%. Within this context, Rhythm Pharmaceuticals, Inc. occupies a specialized niche targeting rare genetic obesity disorders, a segment that is gaining attention as awareness of genetic conditions increases. The competitive landscape includes companies like Revolution Medicines, Inc. and Nuvalent, Inc., but Rhythm's focus on melanocortin-4 receptor technology sets it apart, particularly in addressing the specific needs of patients with genetic obesity disorders.
Who Are RYTM's Key Customers?
- Patients diagnosed with rare genetic obesity disorders.
- Healthcare providers and specialists in genetic medicine.
- Research institutions focused on obesity and metabolic disorders.
Company Profile
Rhythm Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO David Meeker. RYTM has traded publicly since 2017.
F-Score 3/9Financial Health
Rhythm Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 10.28 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on assets is -45.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.7%, the inverse of the P/E and a quick read on earnings relative to price.
RYTM Valuation & Market Position
With a $7.65B market cap, Rhythm Pharmaceuticals, Inc. sits in the mid-cap segment of the market. Relative to its peer group, RYTM's quantitative score of 23/100 is below the peer average of 51/100.
FY2026 estForward Outlook
Wall Street analysts project Rhythm Pharmaceuticals, Inc. revenue of about $298.1M for fiscal 2026, with EPS near $-3.15. The estimate reflects 12 contributing analysts.
Net buyingInsider Activity
Over the past six months, Rhythm Pharmaceuticals, Inc. insiders filed 29 SEC Form 4 transactions — 15 sales and 14 purchases. On net that is roughly 12K shares acquired (about $568K) — insiders putting money in tends to read as conviction.
RYTM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the potential for growth.
- Community sentiment has shifted positively, with increased discussions around potential drug approvals boosting optimism.
- The company’s focus on rare diseases positions it well in a niche market, attracting interest from specialized investors.
- Recent positive clinical trial results have strengthened the belief in the efficacy of their treatments, enhancing market perception.
Bear Case
- Concerns over regulatory hurdles remain prevalent, as the approval process for new drugs can be unpredictable and lengthy.
- Market sentiment has shown volatility, with bearish discussions around the sustainability of their current product pipeline.
- Recent earnings reports highlighted ongoing financial challenges, leading to skepticism about their long-term viability.
- Increased competition in the rare disease space could threaten Rhythm’s market share and impact future growth prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RYTM Latest News
-
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?
Yahoo! Finance: RYTM News · Jun 22, 2026
-
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
seekingalpha.com · Jun 17, 2026
-
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151
benzinga · Jun 16, 2026
-
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
proactiveinvestors.com · Jun 16, 2026
RYTM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RYTM.
Price Targets
Consensus target: $135.56
RYTM MoonshotScore
What does this score mean?
The MoonshotScore rates RYTM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
Latest Rhythm Pharmaceuticals, Inc. Analysis
Leadership: David Meeker
CEO
David Meeker has extensive experience in the biopharmaceutical industry, having held various leadership roles throughout his career. He holds a medical degree from the University of Pennsylvania and an MBA from Harvard Business School. Prior to joining Rhythm Pharmaceuticals, he served in senior positions at several biotech companies, where he focused on product development and commercialization strategies.
Track Record: Under David Meeker's leadership, Rhythm Pharmaceuticals has successfully launched IMCIVREE and advanced its clinical pipeline, positioning the company for future growth in the rare genetic obesity market.
Common Questions About RYTM (Healthcare)
What does Rhythm Pharmaceuticals, Inc. do?
Rhythm Pharmaceuticals, Inc. specializes in developing and commercializing therapeutics for rare genetic diseases of obesity. Its lead product, IMCIVREE, targets specific genetic deficiencies related to obesity, while the company is also advancing setmelanotide through clinical trials for various genetic obesity disorders. This focused approach positions Rhythm uniquely in the biotechnology sector.
What do analysts say about RYTM stock?
Analysts generally recognize Rhythm Pharmaceuticals, Inc. for its innovative focus on rare genetic obesity disorders, with particular attention on the performance of IMCIVREE. Key valuation metrics include a market cap of $7.65B and a gross margin of 89.4%. Growth considerations revolve around the outcomes of ongoing clinical trials for setmelanotide, which could significantly impact future revenues.
What are the main risks for RYTM?
Rhythm Pharmaceuticals, Inc. faces several risks, including regulatory hurdles that could delay the approval of its new therapies, particularly for setmelanotide. Additionally, the company operates in a highly volatile market, which can lead to fluctuations in stock price. Competition from other biotech firms targeting similar genetic disorders also poses a threat to its market position.
What are the key factors to evaluate for RYTM?
Rhythm Pharmaceuticals, Inc. (RYTM) holds an AI score of 23/100 (low). Analysts target $135.56 (+21%). Not financial advice.
How frequently does RYTM data refresh on this page?
RYTM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RYTM's recent stock price performance?
Rhythm Pharmaceuticals, Inc. (RYTM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong proprietary technology platform targeting genetic obesity disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RYTM overvalued or undervalued right now?
Valuing Rhythm Pharmaceuticals, Inc. (RYTM) requires multiple metrics. Analysts target $135.56 (+21%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RYTM?
Before investing in Rhythm Pharmaceuticals, Inc. (RYTM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of May 2026.